UNITED STATES OMB APPROVAL
 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

OMB Number:      3235-0167

Expires:       July 31, 2024 Estimated average burden

hours per response     1.50

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 000-55453

 

Endonovo Therapeutics, Inc.

 

(Exact name of registrant as specified in its charter)

 

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367

 

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, par value $0.0001

 

(Title of each class of securities covered by this Form)

 

None

 

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

  Rule 12g-4(a)(1) ☐
  Rule 12g-4(a)(2) ☒
  Rule 12h-3(b)(1)(i) ☐
  Rule 12h-3(b)(1)(ii) ☐
  Rule 15d-6 ☐
  Rule 15d-22(b) ☐

 

  Approximate number of holders of record as of the certification or notice date: 426  

 

 

 

 
 

 

Pursuant to the requirements of the Securities Exchange Act of 1934 (Name of registrant as specified in charter) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: February 2, 2024   By: /s/ Alan Collier
        Alan B. Collier, CEO

 

SEC 2069 (08-11) Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

 

Instruction: This form is required by Rules 12g-4, 12h-3, 15d-6 and 15d-22 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.

 

2 of 2

Endonovo Therapeutics (PK) (USOTC:ENDV)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Endonovo Therapeutics (PK).
Endonovo Therapeutics (PK) (USOTC:ENDV)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Endonovo Therapeutics (PK).